Source:http://linkedlifedata.com/resource/pubmed/id/11259132
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2001-3-22
|
pubmed:abstractText |
C. Thiffault, L. Lamarre-Théroux, R. Quirion, and J. Poirier (1997, Mol. Brain Res. 44: 238-244) recently reported that chronic treatment of young (12 week old) C57BL/6 mice with (R)-deprenyl, a mechanism-based inactivator of monoamine oxidase B (MAO-B), leads to a more than fourfold increase in neostriatal dopamine levels. Such an effect could complicate the interpretation of results obtained from mechanistic studies designed to evaluate the putative neuroprotective effects of (R)-deprenyl in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned mice. In contrast to the results of Thiffault et al., we have found that neostriatal dopamine levels in mature (32 week old) C57BL/6 mice were unaltered by chronic (R)-deprenyl treatment even though brain monoamine oxidase B activity was reduced by more than 80%. Neostriatal dopamine levels also were unaltered in both young and mature mice when the (R)-deprenyl treatment period was doubled compared to that reported by Thiffault et al. Consequently, studies on the putative neuroprotective properties of (R)-deprenyl in MPTP-lesioned mice are unlikely to be complicated by the possibility that inhibition of MAO-B alone will lead to an increase in neostriatal dopamine levels.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/1-Methyl-4-phenyl-1,2,3,6-tetrahydro...,
http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Monoamine Oxidase,
http://linkedlifedata.com/resource/pubmed/chemical/Monoamine Oxidase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Neuroprotective Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Selegiline
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0014-4886
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
168
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
434-6
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11259132-1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine,
pubmed-meshheading:11259132-Animals,
pubmed-meshheading:11259132-Corpus Striatum,
pubmed-meshheading:11259132-Dopamine,
pubmed-meshheading:11259132-Dopamine Agents,
pubmed-meshheading:11259132-Male,
pubmed-meshheading:11259132-Mice,
pubmed-meshheading:11259132-Mice, Inbred C57BL,
pubmed-meshheading:11259132-Monoamine Oxidase,
pubmed-meshheading:11259132-Monoamine Oxidase Inhibitors,
pubmed-meshheading:11259132-Neuroprotective Agents,
pubmed-meshheading:11259132-Parkinsonian Disorders,
pubmed-meshheading:11259132-Selegiline
|
pubmed:year |
2001
|
pubmed:articleTitle |
Selective inhibition of MAO-B through chronic low-dose (R)-deprenyl treatment in C57BL/6 mice has no effect on basal neostriatal dopamine levels.
|
pubmed:affiliation |
Harvey W. Peters Center, Virginia Tech, Blacksburg, Virginia 24061-0212, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|